Literature DB >> 35068796

A Current Understanding of Bile Acids in Chronic Liver Disease.

Naba Farooqui1, Anshuman Elhence2.   

Abstract

Chronic liver disease (CLD) is one of the leading causes of disability-adjusted life years in many countries. A recent understanding of nuclear bile acid receptor pathways has increased focus on the impact of crosstalk between the gut, bile acids, and liver on liver pathology. While conventionally used in cholestatic disorders and to dissolve gallstones, the discovery of bile acids' influence on the gut microbiome and human metabolism offers a unique potential for their utility in early and advanced liver diseases because of diverse etiologies. Based on these findings, preclinical studies using bile acid-based molecules have shown encouraging results at addressing liver inflammation and fibrosis. Emerging data also suggest that bile acid profiles change distinctively across various causes of liver disease. We summarize the current knowledge and evidence related to bile acids in health and disease and discuss culminated and ongoing therapeutic trials of bile acid derivatives in CLD. In the near future, further evidence in this area might help clinicians better detect and manage liver diseases.
© 2021 Indian National Association for Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  AD, Acute decompensation; ALP, Alkaline phosphatase; AMACR, α-methylacyl-CoA racemase (AMACR); ASBT, Apical sodium dependent bile salt transporter; BA, Bile acid; BSEP, Bile salt export pump; BSH, Bile salt hydrolase; CA, Cholic acid; CDCA, Chenodeoxycholic acid; CLD; CLD, Chronic Liver Disease; CTP, Child-Turcotte-Pugh; CYP7A1, Cholesterol 7 α hydroxylase; DCA, Deoxycholic acid; DR5, Death receptor 5; ELF, Enhanced Liver Fibrosis; FGF-19, Fibroblast growth factor-19; FGFR4, FGF receptor 4; FXR, Farnesoid X receptor; GCA, Glycocholic acid; GDCA, Glycodeoxycholic acid; GLP-1, Glucagon-like peptide1; HBV, Hepatitis B virus; HCV, Hepatitis C virus; HVPG, Hepatic Venous Pressure Gradient; LCA, Lithocholic acid; LPS, Lipopolysaccharide; MELD, Model for End-Stage Liver Disease (MELD); MRI-PDFF, Magnetic resonance imaging derived proton density fat fraction; NAFLD; NAFLD, Non-alcoholic fatty liver disease; NAS, NAFLD activity score; NASH, Nonalcoholic steatohepatitis; NTCP, Sodium taurocholate cotransporting polypeptide; OCA, Obeticholic acid; OST, Organic solute transporter; PBC, Primary biliary cirrhosis; PFIC, Progressive familial intrahepatic cholestasis; PSC, Primary sclerosing cholangitis; PXR, Pregnane X receptor; SHP, Small heterodimer partner; TBA, Total bile acids; TGR5, Takeda G-protein coupled receptor 5; TRAIL, TNF-related apoptosis-inducing ligand; UDCA, Ursodeoxycholic acid; UPLC-MS, Ultra-performance liquid chromatography with tandem mass spectrometry; VDR, Vitamin D receptor; bile acids; cirrhosis; microbiome

Year:  2021        PMID: 35068796      PMCID: PMC8766695          DOI: 10.1016/j.jceh.2021.08.017

Source DB:  PubMed          Journal:  J Clin Exp Hepatol        ISSN: 0973-6883


  135 in total

Review 1.  Bile acid therapy in pediatric hepatobiliary disease: the role of ursodeoxycholic acid.

Authors:  W F Balistreri
Journal:  J Pediatr Gastroenterol Nutr       Date:  1997-05       Impact factor: 2.839

2.  Removal of the bile acid pool upregulates cholesterol 7alpha-hydroxylase by deactivating FXR in rabbits.

Authors:  Guorong Xu; Lu-xing Pan; Sandra K Erickson; Barry M Forman; Benjamin L Shneider; M Ananthanarayanan; Xiaogui Li; Sarah Shefer; N Balasubramanian; Lin Ma; Hitoshi Asaoka; Steven R Lear; Lien B Nguyen; Isabelle Dussault; Frederick J Suchy; G Stephen Tint; Gerald Salen
Journal:  J Lipid Res       Date:  2002-01       Impact factor: 5.922

3.  Clinical, Pathologic, and Genetic Features of Neonatal Dubin-Johnson Syndrome: A Multicenter Study in Japan.

Authors:  Takao Togawa; Tatsuki Mizuochi; Tokio Sugiura; Hironori Kusano; Ken Tanikawa; Takato Sasaki; Fumio Ichinose; Seiichi Kagimoto; Takahisa Tainaka; Hiroo Uchida; Shinji Saitoh
Journal:  J Pediatr       Date:  2018-02-28       Impact factor: 4.406

4.  Serum Bile Acids Are Associated with Pathological Progression of Hepatitis B-Induced Cirrhosis.

Authors:  Xiaoning Wang; Guoxiang Xie; Aihua Zhao; Xiaojiao Zheng; Fengjie Huang; Yixing Wang; Chun Yao; Wei Jia; Ping Liu
Journal:  J Proteome Res       Date:  2016-03-22       Impact factor: 4.466

5.  [Long-term ursodeoxycholic acid treatment of cholestatic liver diseases in childhood--clinical and biochemical effects].

Authors:  R Kardorff; M Melter; B Rodeck; J Brodehl
Journal:  Klin Padiatr       Date:  1996 May-Jun       Impact factor: 1.349

6.  A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis.

Authors:  Vlad Ratziu; Victor de Ledinghen; Fréderic Oberti; Philippe Mathurin; Claire Wartelle-Bladou; Christophe Renou; Philippe Sogni; Marianne Maynard; Dominique Larrey; Lawrence Serfaty; Dominique Bonnefont-Rousselot; Jean-Philippe Bastard; Marc Rivière; Jean Spénard
Journal:  J Hepatol       Date:  2010-10-31       Impact factor: 25.083

7.  Bacterial translocation and changes in the intestinal microbiome in mouse models of liver disease.

Authors:  Derrick E Fouts; Manolito Torralba; Karen E Nelson; David A Brenner; Bernd Schnabl
Journal:  J Hepatol       Date:  2012-02-09       Impact factor: 25.083

Review 8.  Treatment of non-alcoholic fatty liver disease - Current perspectives.

Authors:  Anshuman Elhence
Journal:  Indian J Gastroenterol       Date:  2020-03-09

9.  A randomised, double-blind, placebo-controlled phase 1 study of the safety, tolerability and pharmacodynamics of volixibat in overweight and obese but otherwise healthy adults: implications for treatment of non-alcoholic steatohepatitis.

Authors:  Melissa Palmer; Lee Jennings; Debra G Silberg; Caleb Bliss; Patrick Martin
Journal:  BMC Pharmacol Toxicol       Date:  2018-03-16       Impact factor: 2.483

10.  Placebo-Controlled Randomized Trial of an Intestinal Bile Salt Transport Inhibitor for Pruritus in Alagille Syndrome.

Authors:  Benjamin L Shneider; Cathie Spino; Binita M Kamath; John C Magee; Lee M Bass; Kenneth D Setchell; Alexander Miethke; Jean P Molleston; Cara L Mack; Robert H Squires; Karen F Murray; Kathleen M Loomes; Philip Rosenthal; Saul J Karpen; Daniel H Leung; Stephen L Guthery; Danny Thomas; Averell H Sherker; Ronald J Sokol
Journal:  Hepatol Commun       Date:  2018-09-24
View more
  4 in total

1.  Effects of Fat Type and Exogenous Bile Acids on Growth Performance, Nutrient Digestibility, Lipid Metabolism and Breast Muscle Fatty Acid Composition in Broiler Chickens.

Authors:  Shixia Geng; Yuxin Zhang; Aizhi Cao; Ying Liu; Yuting Di; Juntao Li; Qianqian Lou; Liying Zhang
Journal:  Animals (Basel)       Date:  2022-05-13       Impact factor: 3.231

Review 2.  Farnesoid X Receptor, Bile Acid Metabolism, and Gut Microbiota.

Authors:  Hideki Mori; Gianluca Svegliati Baroni; Marco Marzioni; Francesca Di Nicola; Pierangelo Santori; Luca Maroni; Ludovico Abenavoli; Emidio Scarpellini
Journal:  Metabolites       Date:  2022-07-14

3.  Population pharmacokinetic model to generate mechanistic insights in bile acid homeostasis and drug-induced cholestasis.

Authors:  Véronique M P de Bruijn; Ivonne M C M Rietjens; Hans Bouwmeester
Journal:  Arch Toxicol       Date:  2022-07-25       Impact factor: 6.168

4.  Alcohol-dependent downregulation of apolipoprotein H exacerbates fatty liver and gut microbiota dysbiosis in mice.

Authors:  Yaming Liu; Zhe Wu; Yong Zhang; Binbin Chen; Shuqi Yu; Wanyun Li; Jianlin Ren
Journal:  Lipids Health Dis       Date:  2022-09-19       Impact factor: 4.315

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.